Holen Sie sich die Stockscreener-App
179.51
0.06%
-0.11
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$179.62
Offen:
$180
24-Stunden-Volumen:
1.07M
Relative Volume:
1.04
Marktkapitalisierung:
$19.97B
Einnahmen:
$10.52B
Nettoeinkommen (Verlust:
$999.00M
KGV:
21.47
EPS:
8.3628
Netto-Cashflow:
$1.22B
1W Leistung:
-1.70%
1M Leistung:
-2.60%
6M Leistung:
+1.17%
1J Leistung:
+13.28%
1-Tages-Spanne:
$178.95
$180.99
1-Wochen-Bereich:
$178.61
$185.12
52-Wochen-Spanne:
$148.70
$197.55
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Vergleichen Sie DGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
179.51 | 19.98B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
573.81 | 211.55B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
230.42 | 157.68B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
701.83 | 55.82B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
143.47 | 39.81B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
222.92 | 37.14B | 15.90B | 1.28B | 2.21B | 7.2842 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
California Public Employees Retirement System Reduces Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Marshall Wace LLP Reduces Position in Quest Diagnostics Incorporated $DGX - MarketBeat
First Trust Advisors LP Sells 114,868 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Invesco Ltd. Raises Position in Quest Diagnostics Incorporated $DGX - MarketBeat
New York State Common Retirement Fund Sells 7,619 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Can Quest Diagnostics Incorporated (QDI) stock hold up in economic slowdownTrade Exit Report & Safe Entry Zone Identification - Newser
Looking Into Quest Diagnostics Inc's Recent Short Interest - Benzinga
Will Quest Diagnostics Incorporated stock outperform benchmarksJuly 2025 Trends & Real-Time Chart Breakout Alerts - Newser
1,325,624 Shares in Quest Diagnostics Incorporated $DGX Purchased by Norges Bank - MarketBeat
Korea Investment CORP Purchases 12,300 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Published on: 2025-12-03 05:06:27 - Newser
Blueshift Asset Management LLC Has $636,000 Stock Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Is Quest Diagnostics Incorporated (QDI) stock ideal for retirement investorsPortfolio Performance Report & Daily Volume Surge Signals - Newser
Is Quest Diagnostics Incorporated stock nearing a technical breakoutExit Point & Expert Approved Momentum Ideas - Newser
Mackenzie Financial Corp Has $28.11 Million Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Schroder Investment Management Group Buys 122,646 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Is Quest Diagnostics Incorporated stock cheap vs fundamentalsJuly 2025 Snapshot & AI Forecasted Stock Moves - Newser
Why analysts maintain buy rating on Quest Diagnostics Incorporated stockBreakout Watch & Low Drawdown Momentum Ideas - Newser
Russell Investments Group Ltd. Acquires 25,768 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Published on: 2025-12-02 04:36:26 - Newser
How cyclical is Quest Diagnostics Incorporated stock compared to rivals2025 Analyst Calls & Real-Time Chart Breakout Alerts - Newser
Distillate Capital Partners LLC Sells 4,577 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Hsbc Holdings PLC Reduces Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock - sharewise.com
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors - MarketWatch
Quest Diagnostics, Octave Collaborate to Expand Multiple Sclerosis Disease Activity Test Access - marketscreener.com
Octave Bio lands massive deal with Quest Diagnostics that will expand reach of its multiple sclerosis tests - The Business Journals
Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave - Business Wire
First National Advisers LLC Purchases Shares of 8,980 Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Insider Sold Shares Worth $10,589,760, According to a Recent SEC Filing - marketscreener.com
Skandinaviska Enskilda Banken AB publ Raises Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
J. Davis Sells 55,093 Shares of Quest Diagnostics (NYSE:DGX) Stock - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Sold by Grantham Mayo Van Otterloo & Co. LLC - MarketBeat
Northwest & Ethical Investments L.P. Invests $1.10 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Stock Holdings Lifted by Franklin Resources Inc. - MarketBeat
Prudential Financial Inc. Grows Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Does Quest Diagnostics Offer Value After 8% Surge and New Partnerships in 2025? - Yahoo Finance
Insider Sell: Vicky Gregg Sells Shares of Quest Diagnostics Inc (DGX) - GuruFocus
Chmn Davis Sells 55,093 ($10.6M) Of Quest Diagnostics Inc [DGX] - TradingView
Dir Gregg Sells 1,250 ($239.7K) Of Quest Diagnostics Inc [DGX] - TradingView
Quest Diagnostics (DGX) CEO James E. Davis exercises options and sells common stock - Stock Titan
[Form 4] QUEST DIAGNOSTICS INC Insider Trading Activity - Stock Titan
Advisors Asset Management Inc. Reduces Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Can Quest Diagnostics Incorporated stock deliver sustainable ROEQuarterly Profit Report & AI Driven Stock Price Forecasts - BỘ NỘI VỤ
HOLX vs. DGX: Which Healthcare Diagnostics Stock Is the Better Bet? - Finviz
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term - sharewise.com
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Quest Diagnostics Incorporated $DGX Shares Sold by Legal & General Group Plc - MarketBeat
[144] QUEST DIAGNOSTICS INC SEC Filing - Stock Titan
Dir Gregg Files To Sell 1,250 Of Quest Diagnostics Inc [DGX] - TradingView
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.10%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):